Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 59 min ago
Peer-reviewedCC BY 4.0PLOS One

Clinical outcomes of hyaluronic acid–sorbitol injection in athletes with patellofemoral pain: Evaluation of the potential influence of body mass index

  • Julio Carlos Vélez de Lachica1
  • Susana Serrano2
  • Eduard Vidovic3
  • Antonio Farfan4
4 affiliations
  1. 1Social Security Institute of the State of Mexico and its Municipalities (ISSEMyM), Tlalnepantla, México
  2. 2Star Medica Tlalnepantla, Tlalnepantla, México
  3. 3Medical Department, Aptissen SA, Plan-les-Ouates, Switzerland
  4. 4Instituto Nacional de Rehabilitación, Ciudad de México, México
Open at sourcePDFDOICite

Abstract

Background: Patellofemoral pain (PFP) is a frequent cause of activity-related knee pain and functional limitation in athletic populations. Elevated body mass index (BMI) may contribute to patellofemoral joint loading, but evidence on hyaluronic acid–sorbitol injection outcomes in athletes with elevated BMI remains limited. Objective: To describe longitudinal changes in knee function and symptoms over 6 months after intra-articular hyaluronic acid–sorbitol injection in athletes with PFP, and to explore whether baseline BMI was associated with post-injection improvement. Methods: This prospective, single-arm, non-randomized interventional study included 60 athletes aged 30–55 years who received a single 4 mL intra-articular hyaluronic acid–sorbitol injection. IKDC and KOOS scores were assessed at baseline, 15 days, 3 months, and 6 months. Longitudinal changes were evaluated using linear mixed models, with generalized estimating equations as a sensitivity analysis; exploratory regression and subgroup analyses assessed the association between BMI and improvement. Results: Mean IKDC and KOOS scores increased from baseline to 6 months, with estimated changes of +18.58 points for IKDC (95% CI 16.81–20.36) and +19.28 points for KOOS (95% CI 17.52–21.04; both p < 0.001). At 6 months, 75.0% of participants reached the predefined IKDC threshold for clinically meaningful improvement and 83.3% reached the KOOS threshold. Participants with BMI ≥ 25 kg/m2 also showed within-group improvement. BMI was not independently associated with improvement rate after adjustment for baseline score; however, the small elevated-BMI subgroup (n = 22) limited these exploratory comparisons, and a clinically relevant difference could not be excluded. Minor local adverse events occurred in 4 of 60 participants and resolved with cryotherapy. Conclusion: Athletes with PFP, including those with elevated BMI, showed consistent improvement in knee function and symptoms over 6 months following hyaluronic acid–sorbitol injection. These findings support intra-articular hyaluronic acid–sorbitol as a feasible, well-tolerated option for athletes with PFP, regardless of body weight. Controlled trials are needed to confirm the treatment’s contribution, given the single-arm design. Trial Registration: CEI/0504/PI/2022; ClinicalTrials.gov NCT05450458.

Related

  1. A 15-year evaluation of two total knee arthroplasty designs : similar patient-reported outcomes and survivorship but divergent patellofemoral and radiological outcomes
    Nick D. Clement, Thomas R. Williamson, Gillian L. Leitch +2
    Bone & joint openPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMCDOAJ
  2. Comparing the Cutaneous Impacts of a Topical Restructuring Serum versus. Injected Hyaluronic Acid (HA) and Their Combination as Potential Anti-Aging Strategies in Chinese Women: An In Vivo Study
    Jing Li, Xingzuo Liu, Liang Zhang +10
    Dermatology and TherapyPeer-reviewedCC BY-NC 4.0Full textGeneral medicinePMCDOAJ
  3. Evaluation of a personalized total iodine dose (TID) combined with fixed injection duration (FID) protocol using high-concentration (400 mgI/mL) iodinated contrast medium in CT portal venography: a randomized trial
    Quantitative imaging in medicine and surgeryPeer-reviewedCC BY-NC-NDFull textMedical imaging & radiologyEurope PMC
  4. Potential Influence of NUCB2 Genetic Variants on the Clinicopathological Features of Patients with Hepatocellular Carcinoma
    Sung-Lin Hu, Hsiang-Lin Lee, Ming-Yu Lien +4
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Evaluation of Transtympanic Steroid Injection Dosage in Treatment of Sensorineural Hearing Loss: A Systematic Review.
    Sanjana Nallapaneni, Naveen S Raj, Margaret P Byars +2
    Journal of otologyPeer-reviewedCC BY-NC-NDFull textNeurologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{lachica2026clinical,
  title = {{Clinical outcomes of hyaluronic acid–sorbitol injection in athletes with patellofemoral pain: Evaluation of the potential influence of body mass index}},
  author = {Julio Carlos Vélez de Lachica and Susana Serrano and Eduard Vidovic and Antonio Farfan},
  journal = {PLOS One},
  year = {2026},
  month = sep,
  doi = {10.1371/journal.pone.0346269},
  url = {https://doi.org/10.1371/journal.pone.0346269},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Clinical outcomes of hyaluronic acid–sorbitol injection in athletes with patellofemoral pain: Evaluation of the potential influence of body mass index
AU  - Julio Carlos Vélez de Lachica
AU  - Susana Serrano
AU  - Eduard Vidovic
AU  - Antonio Farfan
PY  - 2026
DA  - 2026/09/30
JO  - PLOS One
DO  - 10.1371/journal.pone.0346269
UR  - https://doi.org/10.1371/journal.pone.0346269
AB  - Background: Patellofemoral pain (PFP) is a frequent cause of activity-related knee pain and functional limitation in athletic populations. Elevated body mass index (BMI) may contribute to patellofemoral joint loading, but evidence on hyaluronic acid–sorbitol injection outcomes in athletes with elevated BMI remains limited. Objective: To describe longitudinal changes in knee function and symptoms over 6 months after intra-articular hyaluronic acid–sorbitol injection in athletes with PFP, and to explore whether baseline BMI was associated with post-injection improvement. Methods: This prospective, single-arm, non-randomized interventional study included 60 athletes aged 30–55 years who received a single 4 mL intra-articular hyaluronic acid–sorbitol injection. IKDC and KOOS scores were assessed at baseline, 15 days, 3 months, and 6 months. Longitudinal changes were evaluated using linear mixed models, with generalized estimating equations as a sensitivity analysis; exploratory regression and subgroup analyses assessed the association between BMI and improvement. Results: Mean IKDC and KOOS scores increased from baseline to 6 months, with estimated changes of +18.58 points for IKDC (95% CI 16.81–20.36) and +19.28 points for KOOS (95% CI 17.52–21.04; both p < 0.001). At 6 months, 75.0% of participants reached the predefined IKDC threshold for clinically meaningful improvement and 83.3% reached the KOOS threshold. Participants with BMI ≥ 25 kg/m2 also showed within-group improvement. BMI was not independently associated with improvement rate after adjustment for baseline score; however, the small elevated-BMI subgroup (n = 22) limited these exploratory comparisons, and a clinically relevant difference could not be excluded. Minor local adverse events occurred in 4 of 60 participants and resolved with cryotherapy. Conclusion: Athletes with PFP, including those with elevated BMI, showed consistent improvement in knee function and symptoms over 6 months following hyaluronic acid–sorbitol injection. These findings support intra-articular hyaluronic acid–sorbitol as a feasible, well-tolerated option for athletes with PFP, regardless of body weight. Controlled trials are needed to confirm the treatment’s contribution, given the single-arm design. Trial Registration: CEI/0504/PI/2022; ClinicalTrials.gov NCT05450458.
SN  - 1932-6203
ER  -